Citigroup Upgrades Qiagen (NYSE:QGEN) to Hold

Key Points

• Citigroup upgraded Qiagen to “Hold”, joining a broader analyst consensus of “Hold”; four analysts rate the stock a Buy and eleven rate it a Hold, with an average price target of $45.01.
• Qiagen shares opened at $50.36, above the consensus price target, with a market capitalization of $10.38 billion and a P/E ratio of 25.81.
• The company recently exceeded quarterly expectations, reporting $0.62 in earnings per share versus a $0.60 consensus estimate and $535.04 million in revenue; institutional investors own approximately 70% of the stock.

Qiagen (NYSE:QGEN - Get Free Report) was upgraded by equities researchers at Citigroup to a "hold" rating in a research report issued on Monday, Zacks reports.

Other equities analysts have also issued reports about the stock. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the company a "hold" rating in a research report on Tuesday, July 14th. Morgan Stanley reiterated an "overweight" rating on shares of Qiagen in a research note on Friday, September 11th. TD Cowen reissued a "hold" rating on shares of Qiagen in a report on Wednesday, July 15th. Jefferies Financial Group restated a "buy" rating and set a $48.00 price target on shares of Qiagen in a research report on Thursday, August 6th. Finally, Stifel Nicolaus set a $40.00 price target on Qiagen in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $45.01.

Qiagen Trading Down 0.1%

QGEN stock opened at $50.36 on Monday. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The business's 50 day moving average is $44.58 and its 200-day moving average is $42.70. The firm has a market cap of $10.38 billion, a P/E ratio of 25.81, a P/E/G ratio of 5.01 and a beta of 0.61.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The business had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same quarter in the previous year, the firm earned $0.60 EPS. Qiagen's quarterly revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities analysts anticipate that Qiagen will post 2.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of QGEN. Amundi raised its position in shares of Qiagen by 12.4% during the first quarter. Amundi now owns 4,757,681 shares of the company's stock worth $190,498,000 after acquiring an additional 524,959 shares during the last quarter. State Street Corp boosted its holdings in Qiagen by 4.5% in the second quarter. State Street Corp now owns 2,183,206 shares of the company's stock valued at $85,363,000 after acquiring an additional 93,575 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Qiagen by 20.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company's stock valued at $66,649,000 after acquiring an additional 286,665 shares during the last quarter. Swiss National Bank boosted its holdings in Qiagen by 21.1% in the first quarter. Swiss National Bank now owns 716,059 shares of the company's stock valued at $28,686,000 after acquiring an additional 124,920 shares during the last quarter. Finally, Arbejdsmarkedets Tillaegspension increased its position in Qiagen by 24.8% in the first quarter. Arbejdsmarkedets Tillaegspension now owns 636,918 shares of the company's stock worth $25,502,000 after purchasing an additional 126,405 shares during the period. Institutional investors and hedge funds own 70.00% of the company's stock.

Qiagen Company Profile

QIAGEN N.V. NYSE: QGEN is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.